QazCovid-in

QazCovid-inVaccinePhase I/II/IIIThe QazCovid-in vaccine is an inactivated vaccine. Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) and/or by inactivation using a chemical reagent (such as beta-propiolactone or formaldehyde). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.NEWS FEED December 31, 2020The Republic of Khazakstan’s QazCovid-in COVID19 vaccine enters phase 3 with an expected 3000 participants. August 28, 2020QazCovid-in, an inactive viral vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan enters Phase 1/2 clinical trials.ORGANIZATIONSResearch Institute for Biological Safety Problems, National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan, City polyclinic No. 4 of the UZO of Almaty, Clinic of the International Institute of Postgraduate Education, City Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl RegionCOUNTRIES INVOLVED TRIAL PARTICIPANTS

Phase 1: 44

Phase 2: 200

Phase 3: 3000CLINICAL TRIAL NUMBERNCT04530357NCT04691908

QazCovid-in, also known as QazVac, is an inactivated virus vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.^[499]

Kazakhstan^[499]

https://fortune.com/2021/04/26/new-covid-19-vaccine-kazakhstan-qazvac/

A new vaccine on the scene: Kazakhstan begins rollout of homegrown QazVac

The world’s approved COVID-19 vaccines have all come from large economies such as the U.S., China, the U.K., Russia, and India. Until today.

On Monday, Kazakhstan started rolling out its homegrown vaccine, now known as QazVac. Before a rebranding at the end of last month, it was called QazCovid-in, but the central Asian country’s government decided that name might be a turnoff for the public.

The vaccine was developed by Kazakhstan’s Research Institute for Biological Safety Problems, which claimed 96% efficacy in the second stage of clinical trials. The final phase is still ongoing, with a conclusion expected in July, but Kazakh health authorities decided it was fine to begin the rollout as long as the 3,000-participant Phase III trial was at least halfway finished.

This isn’t an adenovirus vector vaccine like those from Johnson & Johnson and AstraZeneca—though it does share their relatively mild refrigeration requirements—nor is it an mRNA-based jab like the BioNTech/Pfizer and Moderna vaccines. Instead, it uses an inactivated form of the SARS-CoV-2 virus itself, much like China’s CoronaVac and India’s Covaxin, which are both in use, and Valneva’s vaccine, which isn’t there yet. The QazVac regimen comprises two doses, to be administered three weeks apart.

‘Turn the tide’

Health Minister Alexei Tsoi was one of the first QazVac recipients on Monday morning. Tsoi was at the start of this month on the receiving end of a public dressing-down by President Kassym-Jomart Tokayev, who was furious about the sluggish start to the country’s inoculation campaign amid rising case numbers.

“You must turn the tide, otherwise a personnel decision that is going to be very disappointing for you will follow,” Tokayev told Tsoi. The vaccination campaign, which had previously focused on frontline workers, then reportedly sprang to life for others too in the oil-rich country.

Thus far, Kazakhstan’s vaccination drive has been powered by Russia’s Sputnik V, which has been produced locally for the past couple of months (Tokayev opted for the Russian shot, rather than waiting for QazVac). By late last week, just over 800,000 people had received their first dose. Kazakhstan has a population of 18.8 million people; the government plans to inoculate 2 million each month.

Tokayev tweeted Friday that domestic production would provide vaccine availability to all citizens. If so, that would be a remarkable turnaround—Almaty health officials said five weeks ago that the largest Kazakh city had run out of vaccines, and mass vaccination would not be realistic in the near future.

QazVac may have given Tokayev the opportunity to praise Kazakhstan’s scientific prowess, but production remains a bottleneck. The first batch to be distributed runs to only 50,000 doses, and the next tranche, to be produced in May, will be of the same volume.

Tsoi said Monday that the Kazakh government was talking to Turkish manufacturers about increasing production capacity.

QazCovid-in, commercially known as QazVac,^[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.^[3][4][5] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.^[6]

Clinical research

QazVac is currently in Phase 3 (III) of the Clinical Trial, which is expected to be fully completed by 9 July 2021.^[7][8] It is unclear when the first preliminary results will be published.^[9][10]

The administration of the vaccine for the general population began at the end of April 2021.^[11] The Research Institute Kunsulu Zakarya’s Director General’s justification is that the trial is almost 50% completed and “people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high”.^[12]

Production

The vaccine was first manufactured by Kazakhstan’s Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.

Beginning in June 2021, the vaccine is slated^[13] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.^[14][15] This will allow for a production capacity of 500,000-600,000 doses per month.^[16] The contract is still being negotiated,^[17] despite earlier claims that suggesting the deal had already been finalized.^[18][19]

Vaccine innoculation

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.^[20] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.^[21]

Authorization

See also: List of COVID-19 vaccine authorizations § QazCovid-in

Characteristics

The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.^[22]

References

1. ^ “Kazakhstan: Officials under fire over vaccination failures | Eurasianet”. eurasianet.org. Retrieved 11 April 2021.
2. ^ INFORM.KZ (31 March 2021). “Vaccination with homegrown QazVac vaccine likely to start in late April”. http://www.inform.kz. Retrieved 11 April 2021.
3. ^ Yergaliyeva A (20 December 2020). “Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in”. The Astana Times. Retrieved 2 March2021.
4. ^ Clinical trial number NCT04691908 for “Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine” at ClinicalTrials.gov
5. ^ “Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine – Full Text View – ClinicalTrials.gov”. clinicaltrials.gov.
6. ^ “Kazakh Biosafety Research Institute Begins Clinical Trials of Another Vaccine Against COVID-19”. The Astana Times.
7. ^ INFORM.KZ (31 March 2021). “Vaccination with homegrown QazVac vaccine likely to start in late April”. http://www.inform.kz. Retrieved 11 April 2021.
8. ^ “QazVac готова и уже на подходе”. Время (in Russian). Retrieved 11 April2021.
9. ^ INFORM.KZ (9 April 2021). “3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15”. http://www.inform.kz. Retrieved 11 April 2021.
10. ^ “Kazakhstan’s COVID-19 vaccine to be bottled in Turkey”. http://www.aa.com.tr. Retrieved 11 April 2021.
11. ^ tengrinews.kz (9 April 2021). “Как правильно применять казахстанскую вакцину QazVac, рассказал ученый”. Главные новости Казахстана – Tengrinews.kz (in Russian). Retrieved 11 April 2021.
12. ^ “QazVac готова и уже на подходе”. Время (in Russian). Retrieved 11 April2021.
13. ^ It’s unclear at which level of preparation the vaccine will be send to Turkey.
14. ^ MENAFN. “Kazakh COVID-19 vaccine to be bottled in Turkey”. menafn.com. Retrieved 11 April 2021.
15. ^ “QazVac готова и уже на подходе”. Время (in Russian). Retrieved 11 April2021.
16. ^ “Kazakhstan Launches Production of First Homegrown Vaccine, ‘QazVac'”. caspiannews.com. Retrieved 26 April 2021.
17. ^ INFORM.KZ (21 April 2021). “Healthcare Ministry comments on production of QazVac vaccine”. http://www.inform.kz. Retrieved 22 April 2021.
18. ^ “К концу апреля в Казахстане будет выпущено 50000 доз собственной вакцины”. “СНГ СЕГОДНЯ” – последние новости стран СНГ читайте на SNG.TODAY. Retrieved 12 April 2021.
19. ^ “Kazakhstan’s COVID-19 vaccine to be bottled in Turkey”. http://www.aa.com.tr. Retrieved 12 April 2021.
20. ^ contributor, Guest (26 April 2021). “Kazakhstan launches QazVac, its own COVID-19 vaccine”. EU Reporter. Retrieved 26 April 2021.
21. ^ “Казахстанскую вакцину QazVac будут разливать в Турции”. informburo.kz(in Russian). 9 April 2021. Retrieved 12 April 2021.
22. ^ INFORM.KZ (26 April 2021). “Health Minister Alexei Tsoi to be one of the first to get homegrown QazCovid-in vaccine”. http://www.inform.kz. Retrieved 26 April 2021.

External links

Scholia has a profile for QazCovid-in (Q99518269).

The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems¹. It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials^2,3.

1. The Astana Times: Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in [Link]
2. The Lancet: COVID-19 response in central Asia [Link]
3. Economic Research Institute: QazCovid-in [Link]

///////////QazVac, COVID 19, vaccine, QazCovid-in, kazakhastan, SARS-CoV-2, corona virus

NEW DRUG APPROVALS

one time

$10.00

Click here to purchase.